Capital Expenditures for Moderna (MRNA)
According to Moderna's latest reported financial statements, the company's current capital expenditures (TTM) is $202.00M USD. Capital expenditures (CapEx) are cash outlays for property, plant, and equipment and other long-lived productive assets — reported on the cash flow statement under investing activities. CapEx funds future capacity (factories, data centers, software, machinery), so rising spend can signal investment in growth, while heavy CapEx reduces free cash flow available to shareholders. We display CapEx as a positive amount (the absolute cash outflow); compare with revenue to gauge capital intensity and with total assets for the asset-base context.
Headline TTM above sums the four reported quarters through (reported ). Chart and table below cover the full reported history back to .
MRNA
Currently viewingCapital ExpendituresSwitch metric
Latest period
$202.00M
YoY change
-81.7%
5Y CAGR
+23.3%
Peak year (2024)
$1.05B
Cumulative capital expenditures
$2.93B
CapEx history chart for Moderna (MRNA) from 2016 to 2025
CapEx history table for Moderna (MRNA) from 2016 to 2025
| Fiscal year | Period ended | Reported | Capital Expenditures | YoY |
|---|---|---|---|---|
| 2025 | $192.00M | -81.7% | ||
| 2024 | $1.05B | +48.7% | ||
| 2023 | $707.00M | +76.8% | ||
| 2022 | $400.00M | +40.8% | ||
| 2021 | $284.00M | +321.1% | ||
| 2020 | $67.45M | +113.8% | ||
| 2019 | $31.55M | -70.2% | ||
| 2018 | $105.77M | +81.1% | ||
| 2017 | $58.40M | +76.2% | ||
| 2016 | $33.14M | — |
CapEx values are taken from Moderna's reported cash flow statements (10-Q quarterly and 10-K annual filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the date the filing was reported; YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
Analysis
In 2025, Moderna (MRNA) capital expenditures totalled $192.00M – plunged 81.7% year-over-year.
Moderna capital expenditures has recorded the values shown across consecutive periods, with a +23.3% compound annual growth rate over 2020–2025 (5 years).
Moderna capital expenditures peaked at $1.05B in 2024; the latest annual figure is $192.00M in 2025 (81.7% below peak).
Across the available history, capital expenditures reached its high of $1.05B in 2024 and its low of $31.55M in 2019.
Among 8 Healthcare peers, Moderna (MRNA) ranks 9th; the peer median for capital expenditures is $3.87B.
Moderna Capital Expenditures by Year
Moderna Capital Expenditures 2025: $192.00M
Moderna capital expenditures in 2025 was $192.00M, plunged 81.7% below 2024.
Moderna Capital Expenditures 2024: $1.05B
Moderna capital expenditures in 2024 was $1.05B, surged 48.7% from 2023. This figure represents the highest annual value in the available history.
Moderna Capital Expenditures 2023: $707.00M
Moderna capital expenditures in 2023 was $707.00M, surged 76.8% from 2022.
Moderna Capital Expenditures 2022: $400.00M
Moderna capital expenditures in 2022 was $400.00M, surged 40.8% from 2021.
Moderna Capital Expenditures 2021: $284.00M
Moderna capital expenditures in 2021 was $284.00M.
See more financial history for Moderna (MRNA).
Sector peers — CapEx
Companies in the same sector as Moderna, ranked by their latest capital expenditures.
| Company | Capital Expenditures | Sector |
|---|---|---|
| Novo Nordisk A/S (NVO) | $90.11B | Healthcare |
| Eli Lilly and Company (LLY) | $7.84B | Healthcare |
| Johnson & Johnson (JNJ) | $4.83B | Healthcare |
| Merck & Co., Inc. (MRK) | $4.11B | Healthcare |
| UnitedHealth Group Incorporated (UNH) | $3.62B | Healthcare |
| AstraZeneca PLC (AZN) | $2.81B | Healthcare |
| Amgen Inc. (AMGN) | $1.86B | Healthcare |
| AbbVie Inc. (ABBV) | $1.21B | Healthcare |
Frequently asked questions
What is Moderna's capital expenditures?
- Latest reported capital expenditures for Moderna (MRNA) is $202.00M (period ending December 31, 2025).
How has Moderna capital expenditures changed year-over-year?
- Moderna (MRNA) capital expenditures changed -81.7% year-over-year on the latest annual filing.
What is the long-term growth rate of Moderna capital expenditures?
- Moderna (MRNA) capital expenditures compound annual growth rate is +23.3% over the most recent 5 years available.
When did Moderna capital expenditures hit its highest annual value?
- Moderna capital expenditures reached its highest annual value of $1.05B in 2024.
What was Moderna capital expenditures in 2024?
- Moderna (MRNA) capital expenditures in 2024 was $1.05B.
What was Moderna capital expenditures in 2025?
- Moderna (MRNA) capital expenditures in 2025 was $192.00M.
Metrics overview
Pick a metric for charts, filings, and peers — each row shows the latest TTM or annual value with year-over-year change.
Explore more
MRNA Overview
Company profile, financial tools, and key metrics
MRNA Revenue Counter
Earns $61.61 every second. See per minute, hour, and day.
MRNA Earnings Counter
Loses −$89.49 per second. See per minute, hour, and day.
MRNA Economic Scale
Exceeds Timor-Leste's GDP. Compare with world economies.
MRNA What If Invested
What if you had invested $1,000? See historical returns from any date.
MRNA How It Makes Money
Discover visual breakdown of $1.94B in revenue — where it comes from and where it goes.
MRNA Stock Seasonality
Best and worst months to invest. Historical monthly returns heatmap.
MRNA Price Target Scenarios
Model bear, base, and bull cases with EPS growth and exit P/E — pre-filled from analysts and history.
MRNA Daily Price Character
Explosive · 48.2% historical win rate (green days). Streaks & record days.
MRNA Buybacks
Recent repurchase activity. Shareholder yield & SBC comparison.